Lastly, high levels of expression of certain tumor-associated antigens (TAAs; CD19, CD20, CD22, and CD38) in most B cell malignancies are correlated with a high proliferation rate and disease progression (Table 1) [14,15,16,17]. This evidence concerns the gene CD22 and neoplasm.